Macrophages occupy a dual biological role. They defend during acute inflammation but can drive chronic inflammatory pathology and, within tumors, shift to an immunosuppressive M2-like state that supports growth and metastasis. The authors reviewed nanomaterial platforms developed to alter these macrophage behaviors by delivering immunomodulatory cargo directly to cells at disease sites. Several mechanistic classes appear repeatedly in the literature: blockade of chemokine recruitment pathways (for example the CCL2-CCR2 axis), induction of apoptosis to selectively deplete macrophage populations, metabolic reprogramming to change functional phenotype, and the use of biomimetic or apoptotic cell-inspired constructs to engage physiological clearance pathways. For antitumor aims, the review summarizes strategies that deliver TLR and STING agonists to stimulate macrophage-mediated immune activation rather than suppression.
The review emphasizes mechanism as the organizing principle. Different mechanisms produce divergent clinical aims: in chronic inflammatory disorders the goal is often to reduce macrophage-driven tissue damage or to promote an M2-like healing phenotype, while in oncology the objective is to convert tumor-associated macrophages from immunosuppressive supporters into immune-stimulatory effectors. The nanoparticle acts as the vehicle that enables local, targeted modulation of macrophage signaling without necessarily relying on systemic exposure to small molecules or biologics.
Nanoparticle surface chemistry, core composition, and the presence of targeting ligands all influence which macrophage subsets are engaged and how those cells respond. The authors point out common design principles across disease contexts: passive accumulation via enhanced permeability and retention (EPR) at sites of inflammation or tumor; and active targeting achieved through ligands that bind macrophage surface receptors. Biomimetic modifications—coating particles with cell-derived membranes or apoptotic-cell mimics—leverage natural recognition and clearance mechanisms to bias uptake and downstream signaling. The review also discusses how particle composition affects payload release, intracellular trafficking, and interaction with innate immune sensors; these material properties therefore shape whether a delivered agent induces apoptosis, alters metabolic pathways, or engages pattern-recognition receptors such as TLR or STING.
Material choices determine more than biodistribution. They can tip the balance between therapeutic reprogramming and unintended activation. The study team observed that carefully tuned surface chemistry and ligand selection are central to achieving the opposite therapeutic outcomes required in inflammatory disease versus cancer, despite shared design features like EPR and biomimetic approaches.
In inflammatory disease settings the literature reviewed favors approaches that limit macrophage-driven chronic inflammation or promote tissue-resolving phenotypes. Examples discussed include inhibiting macrophage recruitment through chemokine-axis blockade, selectively eliminating pathogenic macrophages via apoptosis-inducing payloads, and metabolic reprogramming that shifts cells toward reparative functions. The authors describe apoptotic cell-inspired nanoparticles and other biomimetic constructs that exploit physiologic macrophage clearance pathways to induce or support M2 polarization. These strategies aim to reduce the persistent inflammatory signals that characterize conditions such as rheumatoid arthritis, atherosclerosis, and inflammatory bowel disease. The abstract lists these strategies but does not provide dosing regimens, specific formulations, or detailed outcome measures; such specifics were not reported in the abstract.
The review frames these approaches as complementary: recruitment inhibition reduces influx of inflammatory monocytes, selective depletion removes established pathogenic populations, and metabolic interventions alter the functional programming of macrophages that remain. The authors reported comparative analysis across platforms, focusing on how each design principle contributes to the clinical goal of resolving chronic inflammation.
Tumor-associated macrophages commonly adopt immunosuppressive phenotypes that support angiogenesis and metastasis. The review covers nanoparticle strategies that aim to activate these macrophages, rather than deplete them, to stimulate antitumor immunity. Delivered agonists for innate immune pathways—specifically TLR and STING—feature in multiple nanocarrier designs described by the authors. These agonist-loaded particles seek to reprogram macrophages within the tumor microenvironment, promoting inflammatory signaling and antigen presentation that can amplify adaptive immune responses.
The authors note that tumor-directed designs must reconcile potent local immune activation with safety: activation in the wrong compartment or at supraphysiologic levels risks systemic inflammation. The abstract does not list individual clinical outcomes or trial endpoints for specific nanoparticle therapies; it states that next-generation platforms are progressing into clinical trials for tumor therapy, without enumerating the candidates.
The review identifies novel nanoparticle-based platforms that have advanced into clinical testing for cancer and inflammatory diseases. The authors highlighted these as examples of translational progress, but the abstract does not provide the names of specific agents, trial identifiers, or detailed clinical data. What the review does report is a trend: designs are moving from proof-of-concept in preclinical models toward clinical-stage formulations that incorporate lessons on targeting, payload selection, and biomimetic modification. The authors observed that current clinical efforts reflect convergent design principles—targeted delivery to disease-site macrophages and careful modulation of innate immune sensors.
This section of the review catalogs the emerging clinical presence of nanoparticle immunomodulators while acknowledging that many critical details remain in full-text sources beyond the abstract.
The authors conclude with a focused discussion of barriers that limit broader clinical translation. Chief among these are nanoparticle-related immunotoxicity, which can arise from off-target immune activation or adverse innate responses; the intrinsic heterogeneity of macrophage populations across tissues and disease states, which complicates targeting and predictable functional outcomes; and manufacturing reproducibility, which challenges scale-up and consistent product characterization. These issues, the authors argue, create substantial hurdles for regulatory approval and clinical deployment.
The review raises specific unanswered questions that require resolution: how to standardize nanoparticle production to ensure reproducible biological behavior; how to map macrophage heterogeneity in human disease sufficiently to enable precise targeting; and how to mitigate immunotoxicity while retaining therapeutic potency. The abstract indicates that these topics frame the final portion of the paper and that they remain active areas for research and development.
Limitations documented in the abstract include the lack of detailed clinical trial data within the scope of the review abstract and the absence of specific dosing or formulation parameters in the summary. The authors note ongoing clinical testing of next-generation nanoparticle platforms but do not specify trial identifiers or outcomes in the abstract.